The post-prandial state and cardiovascular disease: Relevance to diabetes mellitus

Diabetes/Metabolism Research and Reviews

Volumn 16, Issue 2, 2000, Pages 125-132

  Ceriello, Antonio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Cardiovascular disease; Oxidative stress; Post prandial hyperglycemia; Post prandial state

Indexed keywords

ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIPID BLOOD LEVEL; OXIDATIVE STRESS; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; POSTPRANDIAL PERIOD;

EID: 0034005755     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-7560(200003/04)16:2<125::AID-DMRR90>3.0.CO;2-4     Document Type: Review

References (89)

1. McCay CM. Chemical aspects and the effect of diet upon aging. In Problem of Ageing, Cowdry EV (ed.). Baltimore, MD: Williams & Wilkins, Co; 1942; 680-727.
2. Yu BP. Aging and oxidative stress: modulation by dietary restriction. Free Radic Biol Med 1996; 21: 651-668.
3. Wayne EJ, Graybiel A. Observations on the effect of food, gastric distension, external temperature and repeated exercise on angina of effort, with a note on angina sine dolore. Clin Sci (Colch) 1934; 1: 287-304.
4. Goldstein RE, Redwood DR, Rosing DR, Beiser GD, Epstein SE. Alterations in the circulatory response to exercise following a meal and their relationship to post-prandial angina pectoris. Circulation 1971; 44: 90-100.
5. Biston P, Van Cauter E, Ofek G, Linkowski P, Polonsky KS, Degaute JP. Diurnal variations in cardiovascular function and glucose regulation in normotensive humans. Hypertension 1996; 28: 863-871.
6. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986; 112: 432-437.
7. Groot PHE, van Stiphuit WAHJ, Krauss XH, Jansen H, vanTol A, van Ramshorst E, Chin-On S, Cresswell SR, Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb Vasc Biol 1991; 11: 653-662.
8. Patsch JR, Hopferwieser T, Miesenboeck G, Muehlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. The relationship of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb Vasc Biol 1992; 12: 1336-1345.
9. Ruy JE, Howard G, Craven TE, Bond MG, Hagaman AP, Crouse JR. Postprandial triglyceridemia and carotid atherosclerosis in middleaged subjects. Stroke 1992; 23: 823-828.
10. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAAM 1986; 256: 2835-2838.
11. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
12. McKeone BJ, Patsch JR, Pownal HJ. Plasma triglycerides determine low density lipoprotein composition, physical properties and cell specific binding. J Clin Invest 1993; 91: 1926-1933.
13. Lechleitner M, Hoppichler F, Föger B, Patsch JR. Low-density lipoproteins of postprandial state induce cellular cholesteryl ester accumulation in macrophages. Arterioscler Thromb Vasc Biol 1994; 14: 1799-1807.
14. Goldstein JL, Yo YK, Brown MS, Innerarity TL, Mahley RW. Cholestryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolaemic canine beta-very low density lipoproteins. J Biol Chem 1980; 255: 1839-1848.
15. Mahley RW, Innerarity TL, Brown MS, Ho YK, Goldstein JL. Cholesteryl ester synthesis in macrophages: stimulation by beta-very low density lipoproteins from cholesterol-fed animals of several species. J Lipid Res 1980; 21: 970-980.
16. Patsch JR, Prasad S, Gotto AM Jr, Patsch W. High-density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest 1987; 80: 341-347.
17. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71: 699-708.
18. Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb Vasc Biol 1997; 17: 1539-1544.
19. Marcman P, Sandström B, Jespersen J. Effects of total fat content and fatty acid composition in diet on factor VII coagulant activity and blood lipids. Atherosclerosis 1990; 80: 227-233.
20. Connelly JB, Roderick PJ, Cooper JA, Meade TW, Miller GJ. Positive association between self-reported fatty food consumption and factor VII coagulant activity, a risk factor for coronary heart disease, in 4246 middle-aged men. Thromb Haemost 1993; 70: 250-252.
21. Miller GJ, Martin JC, Mitropoulos KA, Reevens BEA, Thompson RL, Meade TW, Cooper JA, Cruickshank JK. Plasma factor VII is activated by postprandial triglyceridemia, irrespective of dietary fat composition. Atherosclerosis 1991; 86: 163-171.
22. Silveira A, Karpe F, Blombäck M, Steiner G, Waldius G. Hamsten A. Activation of coagulation factor VII during alimentary lipemia. Arterioscler Thromb Vasc Biol 1994; 14: 60-69.
23. Silveira A, Karpe F, Johnsson H, Bauer KA, Hamsten A. In vivo demonstration in humans that large postprandial triglyceriderich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Vasc Biol 1996; 16: 1333-1339.
24. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563.
25. Cortellaro M, Cofrancesco E, Boschetti C, et al., for the PLAT Group. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. Arterioscler Thromb Vasc Biol 1993; 13: 1412-1417.
26. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG, on behalf of the ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. Concerted Action on Thrombosis and Disabilities. Circulation 1996; 94: 2057-2063.
27. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Atherosclerosis 1990; 10: 1067-1073.
28. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb Vasc Biol 1991; 11: 1821-1829.
29. Gasser JA, Betteridge DJ. Lipids and thrombosis. Baillières Clin Endocrinol Metab 1990; 4: 923-938.
30. Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
31. Panza JA, Quyyumy A, Brush JE, Epstein SE. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
32. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelium-derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89: 10-18.
33. Lundman P, Eriksson M, Schenck-Gustafsson K, Karpe F, Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation 1997; 96: 3266-3268.
34. Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet 1994; 343: 1199-1206.
35. Cannon RO III. Does coronary endothelial dysfunction cause myocardial ischemia in the absence of obstructive coronary artery disease? Circulation 1997; 96: 3251-3254.
36. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997; 96: 3264-3265.
37. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does Superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991; 88: 10045-10048.
38. Ceriello A, Giugliano D, Quatraro A, Lefebvre PJ. Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci (Colch) 1991; 81: 739-742.
39. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 93: 1107-1113.
40. Solzbach U, Hornng B, Jeserich M, Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 1997; 96: 1513-1519.
41. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholestrol-lowering and antioxidant therapy on endothelial-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-493.
42. Plotnick GD, Corretti MC, Vogel RA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA 1997; 278: 1682-1686.
43. Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, Tonutti L, Taboga C. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care 1998; 21: 1529-1533.
44. Ursini F, Zamburlini A, Cazzolato G, Maiorino M, Bittolo Bon G, Sevanian A. Postprandial plasma lipid hydroperoxides: a possible link between diet and atherosclerosis. Free Radic Biol Med 1998; 25: 250-252.
45. Colwell JA. Vascular thrombosis in type II diabetes mellitus. Diabetes 1993; 42: 8-11.
46. Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998; 15: 188-193.
47. Kuusisto J, Mykkänen L, Pyörälä K, Laaskso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-967.
48. Lehto S, Rönnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 46: 1354-1359.
49. UKPDS. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
50. Turner RC. The UKPDS Prospective Diabetes Study. a review. Diabetes Care 1998; 21 (Suppl. 3): C-35-38.
51. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20: 1822-1826.
52. Hanefeld M, Schmechel H, Schwanebeck U, Lindner J, The DIS Group. Predictors of coronary heart disease and death in NIDDM: The Diabetes Intervention Study experience. Diabetologia 1997; 40 (Suppl. 2): S123-S124.
53. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, Eschwège E. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367.
54. Witztum JL. Role of modified lipoproteins in diabetic macroangiopathy. Diabetes 1997; 46 (Suppl. 2): S112-S114.
55. Santen RJ, Willis PW, Fajan SS. Atherosclerosis in diabetes mellitus: correlations with serum lipid levels, adiposity and serum insulin levels. Arch Intern Med 1972; 130: 833-843.
56. Fuller JH, Keen H, Jarrett RJ, Omer T, Meade TW, Chakrabarti R, North WRS, Stirling Y. Haemostatic variables associated with diabetes mellitus and its complications. Br Med J 1979; 2: 964-966.
57. Cohen RA. Dysfunction of vascular endothelium in diabetes mellitus. Circulation 1993; 87(Suppl. V): V67-V76.
58. Cavallero E, Dachet C, Neufcou D, Wirquin E, Mathe D, Jacotot B. Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels. Metabolism 1994; 43: 270-278.
59. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613-628.
60. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K. Therapeutic potentials of Acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-737.
61. Tsai EC, Hirsch IB, Brunzell JD, Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994; 43: 1010-1014.
62. Jenkins AJ, Klein RL, Chassereau CN, Hermayer KL, Lopes-Virella MF. LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 1996; 45: 762-767.
63. Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Feletto F, Catone B, Taboga C. Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 1999; 48: 1503-1508.
64. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 1988; 31: 889-891.
65. Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E, Pirisi M. Post-meal coagulation activation in diabetes mellitus: the effect of Acarbose. Diabetologia 1996; 39: 469-473.
66. Ceriello A. Fibrinogen and diabetes mellitus. Is it time for intervention trials? Diabetologia 1997; 40: 731-734.
67. Tessari P, Zanetti M, Vettore M, Iori E, Bruttomesso D, Barazzoni R. Effects of metabolic control on fasting and post-meal fibrinogen fractional secretion rate (FSR) in IDDM. Diabetologia 1997; 40 (Suppl. 1): 406.
68. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783-1790.
69. Ceriello A, Motz E, Cavarape A, Lizzio S, Russo A, Quatraro A, Giugliano D. Hyperglycemia counterbalances the anti-hypertensive effect of glutathione in diabetic patients. Evidence linking hypertension and glycemia through the oxidative stress in diabetes mellitus. J Diabetes Complications 1997; 11: 250-255.
70. Marfella R, Verrazzo G, Acampora R, La Marca C, Giunta R, Lucarelli C, Paolisso G, Ceriello A, Giugliano D. Glutathione reverses systemic hemodynamic changes by acute hyperglycemia in healthy subjects. Am J Physiol 1995; 268: E1167-E1173.
71. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-267.
72. Ceriello A. Acute hyperglycaemia and oxidative stress generation. Diabet Med 1997; 14: S45-S49.
73. Mullarkey CJ, Edelstein D, Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 1990; 173: 932-939.
74. Hubinont C, Sener A, Malaisse WY. Sorbitol content of plasma and erythrocytes during short-term hyperglycemia Clin Biochem 1981; 14: 19-20.
75. Ceriello A, Bortolotti N, Crescentini A, Motz E, Lizzio S, Russo A, Ezsol Z, Tonutti L, Taboga C. Antioxidant defenses are reduced during oral glucose tolerance test in normal and non-insulin dependent diabetic subjects. Eur J Clin Invest 1998; 28: 329-333.
76. Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 1994; 94: 771-778.
77. Ceriello A, Giacomello R, Stel G, Motz E, Taboga C, Tonutti L, Pirisi M, Falleti E, Bartoli E. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995; 44: 924-928.
78. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993; 36: 1119-1125.
79. Ceriello A, Quatraro A, Giugliano D. Diabetes mellitus and hypertension. The possible role of hyperglycaemia through oxidative stress. Diabetologia 1993; 36: 265-266.
80. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease. A critical review of epidemilogic and clinical trial data. Ann Intern Med 1995; 123: 860-872.
81. Ceriello A. Dietary antioxidants and diabetes: which ones and when? Abstracts for the 'State of the Art Lectures and Symposia'. 16th International Diabetes Federation Congress, Helsinki 20-25 July 1997, p. 65.
82. Halliwell B, Gutteridge JMC. The antioxidants of human extracellular fluids. Arch Biochem Biophys 1990; 280: 1-8.
83. Gerdes C, Fisher RM, Nicaud V, Boer J, Humphries SE, Talmud PJ, Faergeman O, on behalf of the EARS Group. Lipoprotein lipase variant D9N and N291S are associated with increased plasma triglyceride and lower high-density lipoprotein cholesterol concentrations. Studies in the fasting and postprandial states: the European Atherosclerosis Research Studies. Circulation 1997; 96: 733-740.
84. Silveira A, Green F, Karpe F, Blombäck M, Humphries S, Hamsten A. Elevated levels of factor VII activity in the postprandial state: effect of the factor VII Arg-Gln polymorphism. Thromb Haemost 1994; 72: 734-739.
85. Kubow S. Routes of formation and toxic consequences of lipid oxidation products in foods. Free Radic Biol Med 1992; 12: 63-81.
86. Ceriello A, Quatraro A, Giugliano D. New insights on non-enzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. Diabet Med 1992; 9: 297-299.
87. Blankenhorn DH, Johnson RL, Mack WJ, El Zein HA, Vailas LI. The influence of diet on the appearance of new lesions in human coronary arteries. JAMA 1990; 263: 1646-1652.
88. Koschinky T, He CJ, Mitsuhashi T, Bucala R, Lin C, Buenting C, Heitmann K, Vlassara H. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 1997; 94: 6474-6479.
89. Zilversmit DB. Atherogenesis: a post-prandial phenomenon. Circulation 1979; 60: 473-485.